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In Brief
Quantifying B cells capable of producing broadly neutralizing antibodies against influenza serves as a metric to guide the development of a universal influenza vaccine.
Accession Numbers 5K9J 5K9K 5K9O 5K9Q 5KAN 5KAQ KX386124-KX387227
INTRODUCTION
Influenza A viruses can be categorized into two phylogenetic groups (group 1 and group 2), each containing diverse subtypes ( Figure 1A ). Currently, group 1 influenza viruses from the H1 subtype (1918 and 2009 H1N1 pandemics) , and the group 2 H3 subtype (1968 H3N2 pandemic), co-circulate and cause seasonal infections in over 10% of the human population each year. Other subtypes have emerged or threaten to re-emerge including the group 1 H2 subtype, endemic in humans from 1957-1968, the group 1 H5 subtype, which includes lethal avian strains (Subbarao et al., 1998) , and the group 1 H6 and H9 and the group 2 H7 and H10 subtypes, which have been associated with human infections and fatalities in recent years (Butt et al., 2005; Morens et al., 2013) . Frequent zoonotic cross-overs that may cause pandemics of unpredictable frequency and severity highlight the need for a universal influenza vaccine that is capable of eliciting protection against divergent influenza A viruses.
Potential approaches to a universal influenza vaccine involve the elicitation of neutralizing antibodies that recognize the influenza hemagglutinin (HA) from multiple subtypes. One means to accomplish this involves ontogeny-based strategies, which seek to identify antibodies of reproducible classes and to induce similar antibodies by vaccination Lingwood et al., 2012; Pappas et al., 2014) . We consider antibodies to be of the same class when they recognize the same region, employ the same structural mode of recognition, and develop through similar recombination and maturation pathways (Kwong and Mascola, 2012) . Reproducible classes, which are observed in multiple individuals, represent immunological solutions to the challenge of broad influenza A neutralization that might be available to the general human population.
The influenza A-neutralizing stem-directed antibodies that utilize the HV1-69 germline gene are one such multidonor class (Ekiert et Figure S2 ).
(legend continued on next page) et al., 2008) . In terms of reproducibility, the HV1-69-derived antibodies have the additional advantage of utilizing heavy chainonly recognition, and prior studies have shown their vaccineinduced elicitation (Khurana et al., 2013; Ledgerwood et al., 2011 Ledgerwood et al., , 2013 Sui et al., 2009; Wheatley et al., 2015; Whittle et al., 2014) . However, HV1-69-derived antibodies generally do not neutralize both group 1 and group 2 strains of influenza A, and, only a single HV1-69-derived antibody has been identified (CR9114) capable of neutralizing both group 1 and group 2 strains of influenza A (Dreyfus et al., 2012) . Other broadly neutralizing antibodies have been identified, such as FI6v3 and 39.29, both of which derive from the HV3-30 germline gene; however, co-crystal structures with HA reveal different modes of recognition (Corti et al., 2011; Nakamura et al., 2013) , and FI6v3 and 39.29 are thus not members of the same class. Indeed, a reproducible antibody class capable of neutralizing both group 1 and group 2 influenza A viruses has not been observed in multiple donors.
We previously showed that subjects enrolled in the phase I clinical trial, VRC 310-who received an A/Indonesia/05/2005 monovalent inactivated virus (MIV) vaccine primed by an H5 DNA plasmid vaccine (Ledgerwood et al., 2011 (Table  S1A )-showed transient expansion of H1-and H5-cross-reactive memory B cells specific to the HA stem (Wheatley et al., 2015; Whittle et al., 2014) . To determine whether these memory B cells might encode multidonor class antibodies capable of neutralizing group 1 and group 2 influenza A virus, we sorted memory B cells that reacted with both H5 (group 1) and H3 (group 2) HAs. Immunoglobulin transcripts from post-vaccination cross-reactive memory B cells were sequenced, and the encoded antibodies were synthesized and characterized. Specifically, we assessed breadth and potency of influenza A virus neutralization, determined representative crystal structures in complex with HA, analyzed sequence convergence based on V(D)J-gene recombination and somatic hypermutation (SHM), and tested sequence signatures for their ability to identify group 1 and group 2 neutralizing antibodies. Our findings reveal reproducible immunological pathways to achieve broadly reactive antibodies and support a B cell ontogeny-based approach to obtaining a universal influenza A vaccine.
RESULTS

Identification of Memory B Cells Cross-Reactive with Group 1 and Group 2 Influenza A HAs
We studied ten subjects from the VRC 310 H5N1 vaccine trial who displayed a range of vaccine-elicited serum H5N1 neutralization activity, as well as varied but detectable responses against group 2 strains A/Hong Kong/1-4-MA21-1/1968 (H3N2) or A/Netherlands/219/2003 (H7N7) (Figures 1B and S1 ; Tables S1B and S2). We used recombinant group 1-specific (H5) and group 2-specific (H3) HA probes-modified to prevent sialic acid binding (HADSA) (Wheatley et al., 2015; Whittle et al., 2014) -to co-stain and sort peripheral blood mononuclear cells (PBMCs) isolated 2 weeks post H5N1 MIV boost ( Figures 1C and S2 ). We recovered sequences of memory B cell immunoglobulin gene transcripts from six of the ten studied subjects ( Figure 1D ).
The sequence repertoire of each subject was generally dominated by clonally related transcripts comprising a small number of clonal expansions. Transcripts derived from diverse HV genes including HV1-18, HV3-23, HV3-64D, HV4-30, HV4-34, and HV6-1 (Figures 1D and 1E) . Notably, transcripts from HV1-69, which often predominate group 1-specific stem-reactive antibodies (Lingwood et al., 2012; Pappas et al., 2014; Wheatley et al., 2015) (Table S3) showed surprising similarity. Notably, many immunoglobulin sequences from different donors derived from the same genetic elements ( Figure 1E ). To analyze commonalities of immunoglobulin transcripts between subjects, we considered the following seven genetic elements: inferred heavy variable (HV), heavy diversity (HD), heavy joining (HJ) genes, third-heavy chain complementarity-determining region (CDR H3) length for heavy chain-gene transcript, inferred light variable (LV) and light joining (LJ) genes, and CDR L3 length for corresponding light chain transcripts ( Figure 1E ). Frequentist analysis indicated the presence of four or more of the same genetic elements in separate lineages to be statistically significant (p % 0.001) ( Figure 1E ), and representative antibodies were cloned and expressed from such lineages. Of note, our antibody nomenclature specifies donor, lineage, and clone; e.g., antibody 56.a.09 ( Figure 1E , third row) is named for subject (56), lineage within this subject (a), and clone within this lineage (09). Most of the expressed antibodies bound HA, and all antibodies that bound HA competed with the antigen-binding fragment (Fab) of the stem-directed antibodies CR9114 (Dreyfus et al., 2012) or F10 (Sui et al., 2009) (Figure 1E ), and negative stain-electron microscopy (EM) indicated binding to the HA stem ( Figure S3 ). Most of these antibodies neutralized viruses from both group 1 and group 2, including subtypes H1, H3, H5, and H7, with select antibodies also demonstrating neutralization of viruses from subtypes H2, H9, and H10 (Figures 1E and S4 ; Table S4 ). Notably, in both pseudovirus and microneutralization assays of influenza A viruses, the breadth and potency for several of the newly identified antibodies were comparable to those of antibody CR9114 (Dreyfus et al., 2012) . To understand the immunological basis of these multidonor humoral responses against influenza A, we analyzed the recombination, SHM, and structural constraints, which drove the generation and development of these antibodies. A Multidonor Class of Broadly Neutralizing Antibodies with HV6-1+HD3-3 Germline Genes Three memory B cell lineages, from subjects 31, 54, and 56, shared heavy chain sequences derived from recombination of HV6-1, HD3-3, and HJ4 or HJ5 to yield highly similar amino acid sequences in the CDR H3 ( Figure 1E , top row; Table S3 ). In each case, the heavy chain was paired with a light chain sequence from KV3-20, KJ2, or KJ3 resulting in a CDR L3 of nine amino acids. Similar affinity maturation patterns were observed: a Val100bIle HC alteration of an HD-gene-encoded section of the CDR H3 was completely conserved in all three lineages ( Figure 2A ) (for clarity, each residue number is followed by a subscript denoting parent molecule: HC, heavy chain; LC, light chain; HA1, HA2, or HA, either HA subunit or HA in general Kabat numbering is used for antibodies, thus, residue 100b refers to the second insertion ''b'' after residue 100 [Kabat et al., 1991] ). Notably, these antibodies displayed neutralization breadth and potency that rivaled that of CR9114 and exceeded that of the group-specific CR6261 or CR8020 or of the head-directed antibody CH65 (Ekiert et al., 2009 (Ekiert et al., , 2011 Whittle et al., 2011) (Figures 2B and S4;  Table S4 ).
To provide insight into the structural basis for the similarity between these HV6-1+HD3-3 antibodies, we determined the crystal structure of the antigen-binding fragment (Fab) for antibody, 56.a.09, alone, and in complex with A/Hong Kong/1-4-MA21-1/1968 (H3N2) HA at 3.3 Å resolution (Figures 2C and S5; Tables S5 and S6) . Unexpectedly, the crystallized HA was not trimeric, with the asymmetric unit for the crystallized Fab-H3 complex comprising an HA head of one protomer interacting with the HA stem of an adjacent protomer in a ''head-to-stem'' dimeric arrangement (Figures S5B and S5C) . Despite this nontrimeric arrangement, the Ca-root-mean-square deviation (RMSD) between the 56.a.09-bound HA and the ligand-free HA was <1 Å , and, for clarity, we thus depict the 56.a.09 bound complex as a typical HA trimer ( Figure 2C ).
Antibody 56.a.09 recognized a conserved region on the HA stem in a manner that avoided glycans at residues Asn21 HA1 (conserved on group 1 viruses) and Asn38 HA1 (conserved on group 2 viruses), providing a structural explanation for its extraordinary group 1 and group 2 neutralization breadth. Antibody 56.a.09 bound primarily with its heavy chain (934 Å 2 buried surface area [BSA] versus 386 Å 2 BSA for the light chain). Heavy chain binding involved the HD3-3-encoded CDR H3 ( Figure 2C ) with Phe100 HC and Gly100a HC contributing 240 Å 2 of BSA and the SHM-altered Val100bIle HC inserting directly into the Trp21 HA2 pocket (contributing over 100 Å 2 of interactive surface).
In addition, Met98 HC interacted with a conserved aromatic residue present on all light chains, helping to orient the CDR H3 ( Figure 2D ). Heavy chain binding also involved the HV6-1 germline-encoded CDR H2, which uniquely encodes a nine-amino acid CDR H2, contributed 182 Å 2 of BSA, was unmutated in contact residues in all three subjects ( Figure S6 ), and interacted with the conserved fusion peptide ( Figure 2E ). With respect to light chain, the largely unmutated KV3-20-derived V genes (4%-6% SHM) observed in lineages from these three subjects interacted with the HA stem through both CDR L1 and CDR L3 ( Figure 2F ; Table S6 ), with Tyr33 LC contributing the largest BSA among all light chain residues (73.1 Å 2 ).
HV6-1+HD3-3-derived antibodies were thus found in three independent donors, shared genetic elements in both the heavy and light chain, displayed convergent affinity maturation, and appeared to share the same mode of recognition (structurefunction analysis of recognition interface and SHM are provided in Figure S7 ). Furthermore, we tested for functional complementation: swapping of heavy and light chains of the three HV6-1+HD3-3-derived antibodies resulted in six functional antibodies from nine possible pairings (all three pairings with the heavy chain of antibody 31.g.01 failed to express) (Table S7 ). Overall, these results indicated the HV6-1+HD3-3-derived antibodies form a multidonor class. Structural analysis indicated numerous light chains to be compatible with binding, and 99% of the human population (Abecasis et al., 2012) possess alleles of the HV6-1 and HD3-3 genes compatible with the class elicitation and recognition described here ( Figures 2D-2G ).
A Second Multidonor Class of Broadly Neutralizing
Antibodies with HV1-18+HD3-9 Germline Genes Two memory B cell lineages from subjects 1 and 31 shared immunoglobulin heavy chain sequence derived from recombination of HV1-18 with HD3-9 and HJ4 to yield highly similar amino acid sequences in a CDR H3 of 15 amino acids (Figures 1E and S6) . Notably an Arg96 HC residue was encoded by N-nucleotide addition in both cases ( Figure 3A) . In each donor, the heavy chain was paired with a light chain derived from KV2-30. Encoded immunoglobulins were expressed and shown to neutralize primarily group 1 strains of influenza A, although a few group 2 strains were neutralized ( Figure S4 ; Table S4 ). Overall neutralization from these HV1-18+HD3-9 antibodies appeared more similar to the group 1-specific antibody CR6261 than to the very broad CR9114 or HV6-1-derived antibodies; nevertheless, neutralization breadth encompassed 50% of influenza A subtypes that commonly infect humans ( Figure 3B ).
We determined the crystal structure of Fab 31.b.09 in complex with A/California/04/2009 (pH1N1) HA ( Figure 3C ; Tables S5 and  S6 ). Similar to the 56.a.09-H3 complex structure, the crystallized hemagglutinin in the Fab 31.b.09 complex was not a trimer, but a molecular dimer ( Figure S5 ). Despite this unexpected nontrimeric arrangement, the Ca-RMSD between the 31.b.09-bound HA and the ligand-free HA in the stem region was 0.6 Å , and for clarity, we depict the 31.b.09 bound complex in a more typical trimeric arrangement ( Figure 3C ). The HV1-18+HD3-9-derived antibody 31.b.09 bound an epitope that overlapped the HV6-1+HD3-3 class epitope, but with antibody rotated 105 (mostly involving a rotation perpendicular to the trimer axis) ( Figure 3C ). Antibody 31.b.09 bound with both heavy and light chains (343 Å 2 BSA for heavy chain and 540 Å 2 BSA for the light chain). Heavy chain interactions were generated through CDR H2 and H3 loops. In the CDR H2 (127 Å 2 BSA), the HV1-18 germline-encoded Tyr53 HC recognized the fusion peptide of HA2 and Asn56 HC recognized helix A of HA2, while the CDR H3 (216 Å 2 BSA) was positioned over the fusion peptide-helix A interface with Ile99 HC and Leu100 HC inserting into the hydrophobic groove between these two conserved elements ( Figures 3C-3E ). Light chain interactions involved CDR L1 and L3, which recognized helix A ( Figure 3F ). We tested functional complementation: swapping of heavy and light chains between , and S7 and Tables S3, S4 , S5, S6, and S7.
two antibodies of the putative class resulted in functional antibodies for all four of the possible pairings (Table S7) . Overall, the results indicated the HV1-18+HD3-9-derived antibodies form a multidonor class. The light chain had a 16-amino acid CDR L1, which could be encoded by 12 other LV genes, and residue Ile27e LC , which forms a critical contact, was a product of A Third Multidonor Class of Broadly Neutralizing Antibodies with HV1-18 Germline Gene and Q-x-x-V Motif Multiple B cell lineages in two subjects (16 and 54) produced distinctive HV1-18-derived immunoglobulins sharing five genetic elements and having a CDR H3 of 21 amino acids derived from recombination with either HD2-2 or HD2-15 genes ( Figure 4A ; Table S3 ). This set of immunoglobulins all shared an SHMderived Thr54 HC , a Gln98 HC encoded by P-nucleotide addition, and a germline HD-encoded aliphatic residue at position100a HC (Q-x-x-V motif). Neutralization breadth and potency for this set of immunoglobulins were similar to that of antibody CR9114 (Figure S4 ; Table S4 ), neutralizing all common human-infecting subtypes of influenza A except H2 and exceeding substantially the breadth of group 1-specific or group 2-specific stem antibodies or the head-directed antibody CH65 ( Figure 4B Table S6 ). The CDR H3s of these antibodies also bound the conserved hydrophobic groove next to helix A and adjacent to Trp21 HA2 . The conserved Val100a HC inserted into a pocket present on both group 1 and group 2 HAs, just above Trp21 HA2 and proximal to Ile48 HA2 . Despite differences between residues encoded by HD2-2 (16.a.26) and , the CDR H3s from both antibodies were oriented perpendicular to the Fab axis and interacted similarly with HA. The conserved Gln98 HC interacted with Gln42 HA2 by occupying a germline-encoded pocket unique to HV1-18-encoded antibodies, which was formed by framework residues Gly33 HC and Ser52 HC ( Figures 4E and 4H ). The location of Gln98 HC within the framework pocket likely stabilized the perpendicular orientation of the CDR H3 relative to the antibody-framework regions and may allow for CDR H3-motifs derived from diverse D genes to bind to this conserved hydrophobic groove. In this regard, we note that sequences from subject 01 with an HV1-18 germline gene and a Gln98-x-x-Val100a motif in a 17-amino acid CDR H3 were able to neutralize H3 and H5 strains of influenza. Although light chains of this class contribute approximately one-third of the total buried surface area, analysis of antibodies of this class revealed light chain sequences to derive from diverse LV genes, with only KV3-11 appearing twice. The recently reported HV1-18-derived group 1 and group 2 neutralizing antibody CT149 uses a Gln98 HC -x-xVal100a HC motif with a 19-amino acid CDR H3 to bind the HA stem (Wu et al., 2015) and recognized HA in a manner highly similar to both 16. (Table S7 ). Functionality correlated strongly with HV gene identity and CDR H3 length (Table S7) , suggesting a requirement for specific heavy-light chain pairings. Despite this requirement, the HV1-18 antibodies with Thr54 HC and CDR H3 98 Q-x-x-V motif appeared to form a multidonor class. Thus, the recombination of HV1-18 with many alternative D gene segments yields a Q-x-x-V motif in the CDR H3, which may comprise a common solution for neutralization of group 1 and group 2 influenza A viruses. The many alternative HD gene alleles that can be used to generate CDR H3s for this multidonor class in combination with no obvious light chain bias led to a calculated distribution of potential HV1-18 combinations in the human population of close to 100% (Abecasis et al., 2012) (Figures 4I and 4J ).
Multidonor and Lineage-Unique Antibodies that Neutralize Group 1 and Group 2 Viruses Recognize Similar Epitopes
For the six subjects analyzed, the most highly expanded lineage was lineage ''a'' from subject 31, from which we sequenced 104 clones ( Figure 1E ; Table S2 ). Clone 83 of this lineage (antibody 31.a.83) derived from HV3-23, HD3-9, and HJ6 and displayed the highest neutralization breadth of the antibodies we sequenced and expressed, neutralizing all of the common influenza A subtypes that infect humans ( Figure 5A ). Structural characterization of antibody 31.a.83 in complex with A/Hong Kong/1-4-MA21-1/1968 (H3N2) HA (Table S5 ) revealed binding to the conserved HA stem, primarily through CDR H3 residues, many of which were somatically hypermutated (Figures 5B-5D ; Table  S6 ). Antibody 31.a.83 utilized hydrophobic residues to contact an epitope adjacent to helix A and involving the Trp21 HA2 pocket with its CDR H3 parallel to helix A in a manner that avoided the conserved N-glycan at Asn38 HA1 present in group 2 HAs. A second lineage, ''h'' from subject 56 (lineage 56.h), also derived from the same germline genes as antibody 31.a.83 (Figures 5B and S6) . However, critical CDR H3 contact residues of antibody 31.a.83 were not conserved and a four-amino acid shift relative to the V-gene was observed ( Figure 5B) . Moreover, the representative antibody we expressed and analyzed from this second lineage, antibody 56.h.01, neutralized H1, H2, and H9 subtypes, but not H3, H5, or H7 subtypes (Figures 1E and S4 (legend continued on next page) from the same heavy chain-VDJ genes, but did not use the same mode of recognition nor share convergent development.
Thus, antibody lineages may be multidonor (common or public), meaning that they are observed in different individuals and share the same genetic elements and mode of recognition (Henry Dunand and Wilson, 2015; Zhou et al., 2013) , or unique (uncommon or private), meaning that they have only been observed a single time. We observed no substantial difference between epitopes of multidonor and unique antibodies capable of neutralizing group 1 and group 2 influenza A viruses ( Figures 5E and 5F ), nor did we observe segregation in antibody approach to HA used by multidonor or unique antibodies ( Figures S3E and S3F ). Antibodies from multidonor lineages did, however, have lower SHM (averaging 8% for multidonor versus 11% for the unique). The lower SHM suggested that multidonor antibodies may undergo more parsimonious development. We note that unique lineages (Corti et al., 2011) (Wu et al., 2015) 39.29 HV3-30 10% HV SHM 18aa CDR H3 (Nakamura et al., 2013) CR9114 HV1-69 14% HV SHM 14aa CDR H3 (Dreyfus et al., 2012) (D) Epitope for antibody 31.a.83 (outlined in black) with heavy chain depicted in yellow and junction-encoded residues (highlighted in blue), mutated residues (in red), and germline-encoded residues (in gold) with light chain depicted in tan, HA protomer1 in gray, and HA protomer2 in dark gray. Note that labels for heavychain residues do not explicitly show ''HC''. (E and F) Antibodies capable of neutralizing group 1 and group 2 influenza A viruses recognize overlapping epitopes within the HA stem (colored red). The HA surface is colored blue for structures determined previously (FI6v3 PDB: 3ZTN; 39.29 PDB: 4KVN; CT149 PDB: 4R8W; CR9114 PDB: 4FQI), and gray for structures determined in the current study. See also Figures S3, S4 , S5, and S6 and Tables S3, S4 , S5, S6, and S7.
accounted for the majority of cross-reactive B cells in four of the six analyzed VRC 310 donors (1, 31, 36, and 56) ; in light of the positive functional characteristics of several of the unique lineages (e.g., 31.a.83), it seems likely that these antibodies would contribute to a protective response. As the number of donors with sequenced cross-reactive memory B cells increases, we would expect some of the antibodies described here as ''unique'' to be observed in other donors.
Sequence Signatures for Multidonor Antibody Classes
We analyzed the multidonor antibodies identified here for class-specific sequence signatures ( Figure 6A ) as a means to Control antibodies HV1-18 Q-x-x-V HV1-18+HD3-9 HV6-1+HD3-3 C Figure 6 . Sequence Signatures of Multidonor Antibody Lineages (A) Multidonor class antibodies capable of neutralizing group 1 and group 2 influenza A viruses: sequence signature, number, and frequency of signatureidentified class members. The number of singleton transcripts from 454-derived NGS data is reported in italicized font; these were omitted from transcript and lineage quantifications as described in the Supplemental Experimental Procedures. Additional sequences MEDI8852 (Kallewaard et al., 2016) and SFV005-2G02 (Li et al., 2012) have been identified, which correspond to the HV6-1+HD3-3 and HV1-18+HD3-9 classes, respectively. Figure S6 and Tables S3, S4, and S7. quantify class transcripts and to identify potential class members in other subjects. Notably, despite a sequence signature requiring residue 54 HC to be altered by affinity maturation, the HV1-18 (Q-x-x-V) class accounted for over half of the H5 + and H3 + cross-reactive B cells we sequenced ( Figure 6A ) and could be found in half the analyzed vaccinees ( Figure 6B) . For other subjects, we searched published human antibody datasets, both those with paired heavy-light sequences (DeKosky et al., 2015) , as well as those with heavy chain-only sequences ( Figure 6A ; Table S1C ). Searches with the HV6-1+HD3-3 signature did not yield sequence matches in paired heavy-light sequences, but in the published heavy chain-only datasets, we found 13 matches, which appeared to derive from a single lineage ( Figure S6 ). We chose both consensus as well as the sequence closest to consensus to synthesize and reconstitute with light chains of HV6-1+HD3-3 class antibodies from subjects 54 and 56. One of these reconstituted antibodies did not express, but the other three did and bound H1 HA in a manner that could be competed with antibody F10 ( Figure 6C ). We tested two of these antibodies and both neutralized group 1 and group 2 influenza A strains ( Figure 6D ; Table S3 ), and the neutralization signatures of the synthesized antibodies clustered in a dendrogram with known HV6-1+HD3-3 class antibodies ( Figure 6E ).
With the HV1-18+HD3-9 signature, we found 17 matches in published paired heavy-light chain sequences, which appeared to derive from a single lineage ( Figure 6A ). We synthesized consensus sequences and reconstituted published heavy and light chains as well as the published heavy chain and light chain of this class from subject 31. Both of these reconstituted antibodies bound H1 hemagglutinin in a manner that could be competed with antibody F10 (Figure 6C ), neutralized group 1 influenza A strains ( Figure 6D ; Table S4 ), and clustered in a neutralization dendrogram with known HV1-18+HD3-9 class antibodies ( Figure 6E ). The neutralization breadth of these antibodies was lower than those isolated from VRC 310 subjects, likely due to the use of germline sequences to complete the CDR L1 and CDR L2 regions of this antibody (the somatic mutation of 27E LC to Ile is required for optimal recognition) ( Figure 3F ).
With the HV1-18 (Q-x-x-V) signature, searches did not yield sequence matches in paired heavy-light sequences, but in published heavy chain-only datasets (Table S1C) , we found 244 matches, which appeared to derive from 4 lineages (Figures 6A and S6) . We synthesized four sequences (consensus or closest NGS read) and reconstituted with the five light chains used previously in swapping experiments (Table S7) . None of these reconstituted antibodies bound a set of HAs ( Figure 6C ) or neutralized any of the 15 viruses in our neutralization panel. Analysis of the tested heavy chains indicated that their CDR H3 length matched that of CT149 in three of four cases, but was below the 78% identity threshold that correlated with function in heavy-light complementation of this class (Table S7) .
Altogether, the results indicate sequence signatures with sufficient specificity to identify other functional class members by sequence alone could be obtained for two multidonor classes: HV6-1+HD3-3 and HV1-18+HD3-9. The sequence signature for the third class, HV1-18 (Q-x-x-V), was complicated by incompatibility of some heavy-light pairs from this class; nonetheless, sequence searches for this third class did place an upper limit on the prevalence of this multidonor antibody class in the searched databases.
Vaccine Induction of Multidonor Broadly Neutralizing Antibodies In the VRC 310 trial, we observed a significant expansion (p = 0.0284) of H5 + H3 + memory B cells following H5 DNA prime-MIV boost, ranging from an increase of 1.2-to 10.6-fold ( Figure 7A ). Notably, subjects with the largest increases and the highest frequencies of multidonor antibodies had the largest percentages of antibodies belonging to the three multidonor classes identified here ( Figure 7B ). Our initial observation of a high number of transcripts with multiple genetic commonalities may be explained by the preferential expansion of multidonor class transcripts; indeed, the fold-increase in cross-reactive B cells by subject correlated with the percentage of antibody sequences with inter-subject genetic commonalities ( Figure 7C ). Importantly, the frequency of cross-reactive memory B cells post-VRC 310 vaccination correlated with the sequence signature-identified prevalence of multidonor class antibodies (p = 0.0045) ( Figure S6D ). Moreover, while we did not see significant correlation between fold increase in overall sera titer versus an increase in cross-reactive memory B cells, we did observe a significant correlation in titers with the H1N1 virus, A/Singapore/ 8/1986, which we previously found to be especially sensitive to neutralization by stem-directed antibodies (Lingwood et al., 2012) ( Figure 7D ). To quantify the frequency of multidonor class antibodies in unvaccinated subjects, we examined NGS-determined memory B cell transcripts from healthy normal donors ( Figure 6A ). To compare frequencies from VRC 310-vaccinated versus unvaccinated subjects, we equated the total number of sorted memory B cells with the total number of transcripts and observed a substantially higher transcript frequency (and to a lesser degree, a higher lineage frequency) for multidonor class sequences on H5N1 vaccination in the VRC 310 trial ( Figure 7E ).
We also examined published antibody sequences from subjects immunized with the 2009 or 2010 seasonal influenza vaccine (Jiang et al., 2013) (Figures 6A, 7F , and S6). Overall, transcripts matching the HV1-18+HD3-9 signature were 103 more prevalent prior to vaccination than the other multidonor transcripts; however, this class appeared not to expand on either seasonal or VRC 310 vaccination. By contrast, transcripts matching HV6-1+HD3-3 and HV1-18 (Q-x-x-V) signatures appeared to be present at low frequency prior to vaccination, to increase on seasonal vaccination, and to increase up to 1,000-fold on VRC 310 vaccination ( Figure 7F ).
DISCUSSION
The vaccine induction of broadly neutralizing antibodies against influenza A virus has been a long standing immunological goal. While the human immune system can generate antibodies capable of neutralizing group 1 and group 2 strains of influenza (Corti et Tables S3 and S4 . Wu et al., 2015) , clear evidence of their induction by vaccination had not been reported. In this study, we used a sequence-based structural approach to identify three multidonor classes of antibodies capable of neutralizing group 1 and group 2 influenza A viruses in VRC 310-vaccinated subjects. One multidonor class utilized HV6-1+HD3-3 germline genes ( Figure 2) ; a second class utilized HV1-18+HD3-9 germline genes and a 15-amino acid CDR H3 ( Figure 3) ; and a third class utilized HV1-18 germline gene and a Gln98 HC -x-x-Val100a HC motif (Figure 4) . For each class, we delineated sequence signatures (Figure 6 ). Despite the lack of serological indicators of vaccine-induced improvement in cross neutralization with VRC 310-vaccinated subjects ( Figure S1 ), we observed a significant vaccine-induced expansion of cross-reactive memory B cells ( Figure 7A ) and a clear increase in the frequency of transcripts for two of the multidonor antibody classes ( Figure 7F ). These findings reveal the vaccine induction of broadly neutralizing influenza A antibodies.
Stereotypic antibody signatures have been reported for some bacterial polysaccharide antigens (Adderson et al., 1993) , CD4-induced, V1V2-directed, and VRC01 classes of HIV-1-neutralizing antibodies (Dosenovic et al., 2015; Gorman et al., 2016; Huang et al., 2004; Jardine et al., 2015; Zhou et al., 2013) , and both stem-and head-directed influenza neutralizing antibodies (Pappas et al., 2014; Schmidt et al., 2015) . Thus, despite the potential repertoire of human immunoglobulins being large (Boyd et al., 2009 ) and SHM further increasing diversity to the point where highly similar modes of antigen recognition might be expected very infrequently, our findings reveal that multidonor classes can be induced by vaccination in humans (Figures 7 and S7) .
The coexistence of multiple vaccine-induced pathways to generate influenza group 1 and group 2 neutralizing antibodies is encouraging for efforts aimed at achieving analogous responses in genetically diverse human populations. The stemdirected antibodies induced here potently neutralize in pseudotype assays ( Figure S4 ), but less potently in live influenza A virus assays (Table S4) . While determination of the in vivo concentrations of stem antibodies required for protective efficacy may require passive infusion trials in humans, it seems likely that a protective response will require higher titers of group 1 and group 2 neutralizing antibodies than achieved in the VRC 310 trial. Our NGS-based measurements indicated VRC 310 vaccination to boost the frequency of transcripts from two multidonor classes substantially toward the target goal, and we even observed increases after seasonal vaccination ( Figure 7F ). In this regard, sequence signature-based quantification may provide a suitably sensitive technology to detect transcript frequencies of group 1 and group 2 neutralizing antibodies, to measure their expression in appropriate memory B cell subsets and long-lived plasma cells, and to assess their durability. Appropriate SHM is an additional aspect, which we investigated by analyzing the recognition of germline-reverted versions of each of the three multidonor classes as well as the effect of mutational analysis of critical contacts ( Figure S7 ). Further studies aimed at increasing the prevalence of group 1 and group 2 neutralizing influenza antibody lineages-guided by the sequence signatures identified here-may provide a means to achieve the protective efficacy required of a universal influenza A vaccine. In this regard, it is helpful to know that 100-to 1,000-fold increases in the transcript frequencies for two multidonor classes of influenza A neutralizing antibodies could be achieved through immunization with a divergent influenza (Figures 6A and 7F) , likely by enhancing immune focus to the HA stem ( Figures 7G and 7H ), an approach utilized by ''stem-only'' or ''headless'' immunogens (Impagliazzo et al., 2015; Yassine et al., 2015) and by chimeric HA immunogens (Krammer et al., 2015) . It will be fascinating to evaluate how these immunogens, in various vectored, subunit, and prime-boost combinations, will fare at further inducing, maintaining, or expanding the multidonor broadly neutralizing antibodies identified here.
EXPERIMENTAL PROCEDURES Ethics Statement and VRC 310 Study Design
The VRC 310 study protocol and associated procedures were approved by the National Institute of Allergy and Infectious Diseases (NIAID) Institutional Review Board. All participants provided written informed consent in accordance with the Declaration of Helsinki. The VRC 310 study (ClinicalTrials.gov identifier NCT01086657) (Ledgerwood et al., 2011 was conducted by the Vaccine Research Center, NIH. See Table S1 and the Supplemental Experimental Procedures for details.
Expression of HA Probes, Flow Cytometry, Cell Sorting, and Sequencing HA constructs consisting of the extracellular domain of HA modified to ablate sialic acid binding and C-terminally fused to (1) a T4-fibritin trimerization motif, (2) a biotinylatable AviTag sequence, and (3) a hexahistidine affinity tag were synthesized (Genscript), cloned into a CMV-expression plasmid, and expressed as previously described (Whittle et al., 2014) . Cryopreserved PBMC samples were stained and sorted on a fluorescence-activated cell sorting (FACS) Aria II using fluorescently labeled recombinant H1 (A/New Caledonia/ 20/1999), H5 (A/Indonesia/05/2005), or H3 (A/Perth/16/2009) probes; single memory B cells binding to both H5 and H3 probes were sorted, and sequencing of immunoglobulin genes by multiplex PCR was performed as previously described (Whittle et al., 2014) . See the Supplemental Experimental Procedures for details.
Production of Pseudotyped Lentiviral Vectors and Influenza A Viruses and Measurement of Antibody Neutralizing Activity
Influenza HA pseudotyped lentiviral vectors expressing a luciferase reporter gene were produced and used to infect 293A cells. All influenza viruses used in the microneutralization assays were expanded in Madin-Darby canine kidney epithelial (MDCK) cells in the presence of Tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (Sigma) and titrated in MDCK cells. See the Supplemental Experimental Procedures for details.
Structural Analysis and Sequence Bioinformatics
Both negative stain-EM and X-ray crystallography were used to characterize antibodies from the VRC 310 trial and their complexes with HA. An Antibodyomics1.0 pipeline, modified to analyze both 454 and Illumina output, was used to analyze B cell transcripts for the presence of sequence signatures specific to multidonor antibodies. Frequentist probabilities were used to determine likelihoods of sequence convergence and germline prevalence in the human population. See the Supplemental Experimental Procedures for details.
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